Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Skeletal Muscle Protein Synthetic Response to Amino Acid and Peptides

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03952884
Recruitment Status : Recruiting
First Posted : May 16, 2019
Last Update Posted : August 2, 2019
Sponsor:
Information provided by (Responsible Party):
Nicholas Burd, University of Illinois at Urbana-Champaign

Brief Summary:
Skeletal muscle quality is an important determinant of exercise performance and overall health. It is vital for not just movement, but also metabolizing nutrients. Protein from the diet can promote muscle protein synthesis for muscle recovery and growth. More importantly, doing so shifts net protein balance positively (e.g. protein synthesis is greater than protein breakdown) and promotes greater rates of muscle protein turnover. Leucine is an amino acid required to build muscle, but it also acts as a signaling molecule informing the muscle to start protein synthesis. Before reaching skeletal muscle, dietary protein is digested into small peptides and free amino acids. Rate of absorption from the intestine to the blood stream is significantly faster for peptides compared to amino acids. As amino acid availability in the blood is a precursor for muscle protein synthesis, our objective is to determine if the different absorption rates between free amino acid and peptides influence muscle protein synthetic and breakdown rates.

Condition or disease Intervention/treatment Phase
Protein Metabolism Behavioral: Resistance Exercise Behavioral: No Resistance Exercise Dietary Supplement: Leucine Dietary Supplement: Dileucine Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: Skeletal Muscle Protein Synthetic Response to Amino Acid and Peptides
Actual Study Start Date : May 3, 2019
Estimated Primary Completion Date : December 2019
Estimated Study Completion Date : December 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Leucine
Participants will be allocated to an exercise or non-exercise group. After resistance exercise (or equivalent time point for non-exercise group), participants will consume 2g leucine powder dissolved in 250 mL of water.
Behavioral: Resistance Exercise
Prior to protein consumption participants will perform an acute bout of resistance exercise. They will warm up with two sets of 10 repetitions at 35-75% working load respectively, then perform four working sets of 10-12 repetitions at 65-70% of 1-RM. 1 min, 30 sec rest periods will be implemented between each set.

Behavioral: No Resistance Exercise
Participants allocated to this group will not perform exercise prior to the administration of the nutritional intervention. Participants will remain at rest throughout the trial.

Dietary Supplement: Leucine
Participants will be given 2g of leucine dissolved in 250mL of water. Drink will be consumed immediately after exercise or equivalent time point for non-exercise group.

Experimental: Leucine Peptide (Dileucine)
Participants will be allocated to an exercise or non-exercise group. After resistance exercise (or equivalent time point for non-exercise group), participants will consume 2g protein peptide powder dissolved in 250 mL of water.
Behavioral: Resistance Exercise
Prior to protein consumption participants will perform an acute bout of resistance exercise. They will warm up with two sets of 10 repetitions at 35-75% working load respectively, then perform four working sets of 10-12 repetitions at 65-70% of 1-RM. 1 min, 30 sec rest periods will be implemented between each set.

Behavioral: No Resistance Exercise
Participants allocated to this group will not perform exercise prior to the administration of the nutritional intervention. Participants will remain at rest throughout the trial.

Dietary Supplement: Dileucine
Participants will be given 2g of dileucine dissolved in 250mL of water. Drink will be consumed immediately after exercise or equivalent time point for non-exercise group.




Primary Outcome Measures :
  1. Fractional Synthetic Rate of Mixed Muscle Proteins [ Time Frame: Postabsorptive for 3.5 hours, Postprandial for 3 hours. ]
    Mixed muscle protein synthesis rates will be assessed during the 3.5hr Postabsorptive period (e.g. non-fed state) and the 3hr postprandial period (e.g. fed state) for both experimental interventions (e.g. leucine and leucine peptide). This will allow us to assess the change in fractional synthetic rate from the Postabsorptive period to the postprandial period.

  2. Fractional Synthetic Rate of Myofibrillar Proteins [ Time Frame: Postabsorptive for 3.5 hours, Postprandial for 3 hours. ]
    Myofibrillar muscle protein synthesis rates will be assessed during the 3.5hr Postabsorptive period (e.g. non-fed state) and the 3hr postprandial period (e.g. fed state) for both experimental interventions (e.g. leucine and leucine peptide). This will allow us to assess the change in fractional synthetic rate from the Postabsorptive period to the postprandial period.

  3. Fractional Breakdown Rate of Mixed Muscle Proteins [ Time Frame: Postprandial for 1 hour ]
    Mixed muscle protein breakdown rates will be assessed during the first hour of the postprandial period (e.g. fed state) for both experimental interventions (e.g. leucine and leucine peptide). This will allow us to assess the change in fractional breakdown rate for each respective experimental intervention.


Secondary Outcome Measures :
  1. Phosphorylation of muscle anabolic signaling [ Time Frame: Baseline, immediately after ingestion of leucine/leucine peptides, and 3 hours after ingestion of leucine/leucine peptides ]
    Phosphorylation of anabolic signaling pathways will be assessed in the fasted state and after the ingestion of the experimental interventions.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 35 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Recreationally-active adults: ≥ 30 min of physical activity at moderate intensity ≥ 3 times per week
  • Ages: 18-35 years old
  • English fluency

Exclusion Criteria:

  • Tobacco, nicotine (patch/gum) use (previous 6 mo)
  • Alcohol consumption >10 drinks per week
  • Metabolic disorders (e.g., Metabolic Syndrome, Diabetes, thyroid diseases)
  • Cardiovascular disease, arrhythmias
  • Hypogonadism
  • Asthma
  • History of uncontrolled hypertension
  • Orthopedic injury/surgery (within 1 yr)
  • Hepatorenal, musculoskeletal, autoimmune, or neurological disease
  • History of neuromuscular problems
  • Previous participation in amino acid tracer studies
  • Predisposition to hypertrophic scarring or keloid formation
  • Consumption of ergogenic-levels of dietary supplements that may affect muscle mass (e.g., creatine, HMB), insulin-like substances, or anabolic/catabolic pro-hormones (e.g., DHEA) within 6 weeks prior to participation
  • Consumption of thyroid, androgenic, or other medications known to affect endocrine function
  • Consumption of medications known to affect protein metabolism (e.g., prescription-strength corticosteroids, non-steroidal anti-inflammatories, or acne medication)
  • Currently pregnant

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03952884


Locations
Layout table for location information
United States, Illinois
Freer Hall Recruiting
Urbana, Illinois, United States, 61801
Contact: Nicholas A Burd, Ph.D.    217-244-0970    naburd@illinois.edu   
Sponsors and Collaborators
University of Illinois at Urbana-Champaign
Investigators
Layout table for investigator information
Principal Investigator: Nicholas A. Burd, Ph.D. University of Illinois at Urbana-Champaign
  Study Documents (Full-Text)

Documents provided by Nicholas Burd, University of Illinois at Urbana-Champaign:
Informed Consent Form  [PDF] June 20, 2019


Layout table for additonal information
Responsible Party: Nicholas Burd, Assistant Professor, University of Illinois at Urbana-Champaign
ClinicalTrials.gov Identifier: NCT03952884     History of Changes
Other Study ID Numbers: 18897
First Posted: May 16, 2019    Key Record Dates
Last Update Posted: August 2, 2019
Last Verified: July 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Nicholas Burd, University of Illinois at Urbana-Champaign:
Metabolism
Amino Acid Peptides
Muscle Protein Synthesis
Muscle Protein Breakdown